Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
02 07 2020
Historique:
received: 04 06 2020
revised: 29 06 2020
accepted: 30 06 2020
entrez: 8 7 2020
pubmed: 8 7 2020
medline: 21 11 2020
Statut: epublish

Résumé

In view of an efficient use of the Italian National Health Service-funded healthcare resources, a novel data-processing strategy combining information from multiple sources was developed in a regional cancer network of northern Italy. The goal was to calculate the annual overall cost of care pathways of six disease groups in 10,486 patients. The evaluation was conceived as a population-based cost description from the perspective of the Italian National Health Service. Costs occurred during a defined time period for a cross-section of patients at varying stages of their disease were measured. The total cancer care cost was €81,170,121 (11.1% of total local health expenditure), with a cost per patient of €7741.17 and a cost per capita of €204.62. Surgical, inpatient and day-hospital medical admissions, radiotherapy, drugs, outpatient care, emergency admissions, and home and hospice care accounted for 21.2%, 24.1%, 6.2%, 28.2%, 14.0%, 0.9%, and 5.4% of the total cost, respectively. The highest cost items included drugs (cost per capita, €22.95; 11.2% of total cost) and medical admissions (€14.51; 7.1%) for blood cancer, and surgical (€14.56; 7.1%) and medical admissions (€13.60; 6.6%) for gastrointestinal cancer. The information extracted allows multidisciplinary cancer care teams to be more aware of the costs of their clinical decisions.

Identifiants

pubmed: 32630745
pii: ijerph17134765
doi: 10.3390/ijerph17134765
pmc: PMC7369964
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Breast. 2017 Aug;34:103-107
pubmed: 28558338
BMC Med. 2007 Jun 13;5:15
pubmed: 17567904
J R Soc Med. 2017 Apr;110(4):138-143
pubmed: 28397591
J Interprof Care. 2009 Nov;23(6):599-610
pubmed: 19842953
Eur J Cancer. 2008 Jul;44(10):1345-89
pubmed: 18280139
Lancet Oncol. 2016 Sep;17(9):1196
pubmed: 27476616
Cancer Causes Control. 2010 Dec;21(12):1987-94
pubmed: 20938732
Dev Health Econ Public Policy. 2014;12:133-54
pubmed: 24864385
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Cancer. 2016 Apr 1;122(7):1078-84
pubmed: 26773823
Ecancermedicalscience. 2017 Sep 06;11:765
pubmed: 28955401
JAMA. 2017 Jan 24;317(4):388-406
pubmed: 28118455
Lancet Haematol. 2016 Aug;3(8):e353-4
pubmed: 27476782
Eur J Cancer. 2016 Oct;66:162-70
pubmed: 27589247
Epidemiol Prev. 2009 Jul-Oct;33(4-5 Suppl 1):1-168
pubmed: 20124636
Cancer Causes Control. 2010 Dec;21(12):1967-77
pubmed: 21069448
J Med Econ. 2015 Jan;18(1):29-36
pubmed: 25268728
Lancet Oncol. 2017 Jun;18(6):823-834
pubmed: 28457708
Lancet Haematol. 2016 Aug;3(8):e362-70
pubmed: 27476787
J Hosp Infect. 2011 Nov;79(3):231-5
pubmed: 21868128
Pharmacoeconomics. 2007;25(7):537-62
pubmed: 17610336
Front Public Health. 2017 Feb 27;5:23
pubmed: 28289676
Occup Environ Med. 1996 Oct;53(10):652-7
pubmed: 8943828
Semin Oncol. 2018 Oct;45(5-6):259-263
pubmed: 30482634
Pharmacoeconomics. 2003;21(6):383-96
pubmed: 12678566
BMJ. 2010 Apr 14;340:c1999
pubmed: 20392776
Lancet Oncol. 2014 Jan;15(1):23-34
pubmed: 24314615
Eur J Cancer. 2006 Oct;42(15):2480-91
pubmed: 16904313
Tumori. 2015;101 Suppl 1:S55-9
pubmed: 27096275
Am J Manag Care. 2012 Sep;18(9):525-32
pubmed: 23009303
Radiother Oncol. 2016 Dec;121(3):468-474
pubmed: 28007378
JAMA Oncol. 2017 Apr 1;3(4):524-548
pubmed: 27918777
Value Health. 1998 Nov;1(4):251-9
pubmed: 16674550
Int J Integr Care. 2012 Sep 18;12(Spec Ed Integrated Care Pathways):e192
pubmed: 23593066
Front Oncol. 2016 Jan 28;6:1
pubmed: 26858933
Epidemiol Prev. 2014 Nov-Dec;38(6 Suppl 1):1-122
pubmed: 25759295
Tumori. 2018 Jan-Feb;104(1):51-59
pubmed: 29218691
Eur J Cancer. 2006 Oct;42(15):2459-62
pubmed: 16934974
Lancet Oncol. 2013 Nov;14(12):1165-74
pubmed: 24131614

Auteurs

Mattia Altini (M)

Healthcare Administration, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.

Laura Solinas (L)

Management and Accounting Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.

Lauro Bucchi (L)

Romagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.

Nicola Gentili (N)

Information Technology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.

Davide Gallegati (D)

Management and Accounting Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.

William Balzi (W)

Healthcare Administration, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.

Fabio Falcini (F)

Romagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.
Cancer Prevention Unit, Morgagni-Pierantoni Hospital, 47121 Forlì, Italy.

Ilaria Massa (I)

Unit of Biostatistic and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH